Prostate Health: When to Get a PSA Test and What Your Results Actually Mean

PSA, or prostate-specific antigen, is a protein produced by both normal and cancerous prostate cells. A small amount naturally enters the bloodstream and can be measured with a simple blood test. An elevated PSA does not diagnose prostate cancer — it is a screening signal that prompts further evaluation. PSA is also elevated by benign prostatic hyperplasia (enlarged prostate), prostatitis (prostate inflammation or infection), vigorous exercise, recent sexual activity, and even a digital rectal exam. The history and interpretation of PSA screening have been contentious in medicine — precisely because elevated PSA leads to biopsies, some of which find cancers that would never have caused harm and would be better left alone, while others find life-threatening disease that benefits enormously from early detection. Understanding this nuance is essential to making informed decisions about your own screening.

What Is the Prostate and What Does It Do?

The prostate is a walnut-sized gland (approximately 20–30 mL in volume when young and healthy) located below the bladder and in front of the rectum, surrounding the urethra at its junction with the bladder. Its primary function is to produce seminal fluid, which nourishes and transports sperm. It is under androgenic control — testosterone and dihydrotestosterone (DHT) drive its growth and function throughout life.

Three conditions account for the vast majority of clinically significant prostate problems: benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer. All three can elevate PSA, which is why the test requires thoughtful interpretation rather than a simple cutoff-based reaction.

Normal PSA Ranges by Age

PSA levels naturally increase with age because the prostate grows with age (a process distinct from cancer), and more prostate tissue means more PSA production. Age-specific reference ranges are more clinically useful than a universal cutoff:

• Ages 40–49: 0–2.5 ng/mL considered normal
• Ages 50–59: 0–3.5 ng/mL considered normal
• Ages 60–69: 0–4.5 ng/mL considered normal
• Ages 70–79: 0–6.5 ng/mL considered normal

The traditional cutoff of 4.0 ng/mL as a universal threshold is still widely used but increasingly recognized as imprecise. Approximately 15% of men with a PSA below 4.0 ng/mL have prostate cancer detectable on biopsy, and roughly 25% of high-grade cancers occur in men with PSA below 4. Conversely, many men with PSA between 4 and 10 ng/mL have benign conditions rather than cancer. Newer risk calculators and biomarkers supplement PSA in decision-making.

PSA Velocity: The Rate of Change Matters

PSA velocity — the rate at which PSA rises over time — provides additional diagnostic information. A rise of more than 0.75 ng/mL per year, or more than 0.35 ng/mL per year in men with lower baseline PSA, increases concern for cancer independent of the absolute value. A PSA that doubles in less than 3 years (PSA doubling time of under 3 years) is a red flag. Conversely, a PSA that has been stable at 3.8 ng/mL for five years is less concerning than one that rose from 2.0 to 3.8 ng/mL in two years.

This is why serial PSA testing, not just a single value, is clinically important. A baseline PSA in your forties, with repeat testing every 1–2 years depending on initial level and risk factors, provides the longitudinal data needed to calculate velocity.

Free PSA vs. Total PSA

PSA in the bloodstream circulates in two forms: bound to proteins (the majority) and unbound or "free." The ratio of free PSA to total PSA provides additional discrimination between benign and malignant causes of elevated PSA, specifically in the gray zone of 4–10 ng/mL:

• Free PSA percentage above 25%: Lower probability of cancer (higher likelihood of BPH)
• Free PSA percentage 10–25%: Intermediate risk
• Free PSA percentage below 10%: Higher probability of cancer; biopsy more strongly indicated

The free-to-total PSA ratio improves specificity — meaning it reduces unnecessary biopsies in men whose elevated PSA is due to BPH — without sacrificing sensitivity for meaningful cancer detection.

When Should Men Start PSA Screening?

Screening guidelines vary by organization, but the current evidence-based approach is nuanced:

The United States Preventive Services Task Force (USPSTF) recommends that men aged 55–69 make an individual decision about PSA screening in consultation with their physician, acknowledging both potential benefit (detecting cancer early enough to cure it) and potential harm (false positives leading to unnecessary biopsy and treatment, and overdiagnosis of cancers that would never have caused clinical problems).

The American Urological Association (AUA) recommends discussing PSA screening beginning at age 40 for men at high risk — specifically men with a first-degree relative diagnosed with prostate cancer before age 65, Black men (who have a 70% higher incidence of prostate cancer and higher mortality from it), men with known BRCA2 mutations, and Lynch syndrome carriers. For average-risk men, routine discussion beginning at age 50 is appropriate.

Black men warrant specific emphasis: prostate cancer rates in Black American men are the highest of any demographic group globally (approximately 1 in 6 will be diagnosed), and they are twice as likely to die from prostate cancer as white men. The biological and socioeconomic drivers of this disparity are both real, and earlier, more consistent screening in this group is justified.

Prostate Cancer vs. BPH vs. Prostatitis

Benign Prostatic Hyperplasia (BPH)

BPH is non-cancerous prostate enlargement that affects more than 50% of men in their sixties and up to 90% of men in their eighties. It causes lower urinary tract symptoms: weak or interrupted urine stream, urgency, frequency (particularly nocturia), feeling of incomplete bladder emptying, and straining to urinate. PSA is commonly elevated in BPH because a larger gland produces more PSA. BPH does not increase the risk of prostate cancer, though both can coexist. Treatment ranges from watchful waiting and lifestyle modification to alpha-blockers (tamsulosin), 5-alpha reductase inhibitors (finasteride), or surgical procedures (TURP) for significant symptoms.

Prostatitis

Prostatitis encompasses bacterial prostate infection (acute or chronic) and non-bacterial pelvic pain syndromes. Acute bacterial prostatitis presents dramatically — high fever, perineal pain, difficulty urinating, and systemic illness. PSA can be dramatically elevated during prostatitis (levels of 20, 50, or even 100 ng/mL are not unusual during acute infection) and should not be interpreted as a cancer signal. PSA should be rechecked 4–6 weeks after a prostatitis episode resolves before any biopsy decision is made.

Prostate Cancer

Prostate cancer is the most commonly diagnosed non-skin cancer in American men, with approximately 299,000 new cases estimated for 2024. Most prostate cancers are adenocarcinomas arising from the peripheral zone of the gland. Early prostate cancer is almost always asymptomatic — symptoms (bone pain, weight loss, difficulty urinating) typically indicate advanced disease. This is precisely why PSA screening matters: it detects cancer while it is still localized and most treatable.

The Biopsy Decision

The standard prostate biopsy is a transrectal or, increasingly, transperineal ultrasound-guided procedure in which 12 or more cores of tissue are taken from systematic regions of the prostate, often with targeted biopsies of any suspicious regions visible on MRI. The decision to biopsy should not be driven by PSA alone. Modern decision-making incorporates:

• PSA density (PSA divided by prostate volume measured on ultrasound — values above 0.15 increase concern)
• Free-to-total PSA ratio
• Multiparametric MRI (mpMRI) of the prostate — a powerful non-invasive tool that risk-stratifies suspicious regions and, in MRI-fusion biopsy, significantly improves detection of clinically significant cancer while reducing detection of low-grade cancer that may not require treatment
• Novel biomarkers: the Prostate Health Index (PHI) and the 4Kscore test combine PSA forms and kallikreins to provide a probability of high-grade cancer; the SelectMDx urine test, ExoDx Prostate test, and others serve as "liquid biopsies" to further refine biopsy decisions

Prostate Cancer Grading and the Biopsy Report

If biopsy finds cancer, it is graded by the Gleason system (now reported as Grade Groups 1–5). Grade Group 1 (Gleason 6) is the lowest-risk category: well-differentiated cancer with very low metastatic potential. Grade Groups 4 and 5 (Gleason 8–10) are high-grade, aggressive cancers. Grade Group 2–3 (Gleason 7) is intermediate risk — the most common grade found at diagnosis.

Active Surveillance

For Grade Group 1 and some Grade Group 2 cancers, active surveillance — close monitoring with periodic PSA, repeat biopsy, and MRI rather than immediate treatment — is now a guideline-recommended standard of care. The goal is to avoid the side effects of treatment (incontinence, erectile dysfunction, bowel changes) in men whose cancer is unlikely to cause harm during their lifetime, while maintaining the option to treat if the cancer progresses. Active surveillance does not mean doing nothing — it means monitoring with intent.

Prostate Cancer Treatment Overview

Treatment for higher-risk or progressive cancer depends on stage and grade and may include: radical prostatectomy (surgical removal, now commonly performed robotically), external beam radiation therapy (often with androgen deprivation therapy for intermediate to high-risk disease), brachytherapy (radiation seeds implanted in the prostate), and for metastatic disease, androgen deprivation therapy (ADT), novel androgen receptor pathway inhibitors (abiraterone, enzalutamide, darolutamide), chemotherapy, and radioligand therapy with lutetium-177 PSMA (for PSMA-positive metastatic castration-resistant prostate cancer).

When to See a Doctor

If you are a Black man or have a family history of prostate cancer, discuss PSA screening starting at age 40. All men should discuss the benefits and limitations of PSA screening with their physician by age 50. If you have lower urinary tract symptoms — slow stream, urgency, nocturia, feeling of incomplete emptying — see a physician regardless of age. Do not wait for symptoms to check PSA if you are in a higher-risk group; the cancers that most benefit from early detection are often completely symptom-free. JourneyDoctors connects you with trained specialists from $19. Start a consultation today — no waiting room, no referral needed.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment.

Frequently Asked Questions

Should I stop sex or exercise before a PSA test?

Yes, for the most accurate result. Ejaculation can transiently elevate PSA by up to 0.8 ng/mL, and vigorous cycling or prostate massage can also cause transient elevation. Most guidelines recommend abstaining from ejaculation for 48 hours and avoiding vigorous cycling for 48–72 hours before PSA testing. A digital rectal exam has a minimal effect on PSA and can generally be performed before the blood draw without significantly affecting the result.

What happens after a high PSA result?

A single elevated PSA should be confirmed with a repeat test in 4–6 weeks (after ruling out prostatitis or other transient causes). If confirmed elevated, further evaluation typically includes free-to-total PSA ratio, a multiparametric MRI, and potentially a novel biomarker test before deciding whether biopsy is warranted. An elevated PSA does not automatically mean a biopsy — the decision is individualized.

Is prostate cancer always slow-growing?

No. This is one of the most dangerous oversimplifications in prostate cancer awareness. Grade Group 1 cancers are genuinely slow-growing and often managed with active surveillance. Grade Groups 4 and 5 are aggressive, can metastasize rapidly, and are a leading cause of cancer death in American men. The behavior of a specific prostate cancer depends entirely on its grade — which can only be determined by biopsy and pathological examination.

Can I have prostate cancer with a normal PSA?

Yes. Approximately 15% of prostate cancers, including some high-grade cancers, occur in men with a PSA below 4.0 ng/mL. PSA is a useful screening tool but not a perfect one. This is why clinical evaluation including symptom history, digital rectal examination findings, and risk factor assessment complements PSA rather than being replaced by it.

Does finasteride or dutasteride affect PSA results?

Yes, significantly. These 5-alpha reductase inhibitors, used for BPH and male pattern hair loss, lower PSA by approximately 50% within 6 months of use. A man on finasteride should have his measured PSA doubled (multiplied by 2) to estimate his true PSA level for screening interpretation purposes. Failing to account for this can mask clinically significant PSA elevation and delay cancer diagnosis.